OncologyNew lung cancer pill beats older KRAS drugs in head-to-head trial
Roche's divarasib kept KRAS G12C lung cancer in check for 9.8 months against 5.7 on sotorasib or adagrasib, and people taking it lived about six months longer.
25 October 2026